247 related articles for article (PubMed ID: 33051247)
1. Pharmacokinetic and Pharmacodynamic Factors Contribute to Synergism between Let-7c-5p and 5-Fluorouracil in Inhibiting Hepatocellular Carcinoma Cell Viability.
Jilek JL; Tu MJ; Zhang C; Yu AM
Drug Metab Dispos; 2020 Dec; 48(12):1257-1263. PubMed ID: 33051247
[TBL] [Abstract][Full Text] [Related]
2. The monoclonal antibody CH12 augments 5-fluorouracil-induced growth suppression of hepatocellular carcinoma xenografts expressing epidermal growth factor receptor variant III.
Jiang H; Dong Q; Luo X; Shi B; Wang H; Gao H; Kong J; Zhang J; Li Z
Cancer Lett; 2014 Jan; 342(1):113-20. PubMed ID: 24007863
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib enhances the chemotherapeutic efficacy of S-1 against hepatocellular carcinoma through downregulation of transcription factor E2F-1.
Zhai JM; Yin XY; Lai YR; Hou X; Cai JP; Hao XY; Liang LJ; Zhang LJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1255-64. PubMed ID: 23435877
[TBL] [Abstract][Full Text] [Related]
4. The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Miyagi T; Hosui A; Tatsumi T; Ishida H; Noda T; Nagano H; Doki Y; Mori M; Hayashi N
J Hepatol; 2010 May; 52(5):698-704. PubMed ID: 20347499
[TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase.
Liao B; Liang H; Chen J; Liu Q; Zhang B; Chen X
Tumour Biol; 2015 Dec; 36(12):9347-56. PubMed ID: 26108995
[TBL] [Abstract][Full Text] [Related]
6. MiR-199a-5p and let-7c cooperatively inhibit migration and invasion by targeting MAP4K3 in hepatocellular carcinoma.
Liu L; Lu L; Zheng A; Xie J; Xue Q; Wang F; Wang X; Zhou H; Tong X; Li Y; Zhu X; Wu G
Oncotarget; 2017 Feb; 8(8):13666-13677. PubMed ID: 28099144
[TBL] [Abstract][Full Text] [Related]
7. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Yamashita M; Wada H; Eguchi H; Ogawa H; Yamada D; Noda T; Asaoka T; Kawamoto K; Gotoh K; Umeshita K; Doki Y; Mori M
Int J Oncol; 2016 Jul; 49(1):89-98. PubMed ID: 27121124
[TBL] [Abstract][Full Text] [Related]
8. Characterization and resistance mechanisms of a 5-fluorouracil- resistant hepatocellular carcinoma cell line.
Gu W; Fang FF; Li B; Cheng BB; Ling CQ
Asian Pac J Cancer Prev; 2012; 13(9):4807-14. PubMed ID: 23167424
[TBL] [Abstract][Full Text] [Related]
9. Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma.
Kataoka J; Shiraha H; Horiguchi S; Sawahara H; Uchida D; Nagahara T; Iwamuro M; Morimoto H; Takeuchi Y; Kuwaki K; Onishi H; Nakamura S; Takaki A; Nouso K; Yagi T; Yamamoto K; Okada H
Oncol Rep; 2016 May; 35(5):2576-82. PubMed ID: 26985715
[TBL] [Abstract][Full Text] [Related]
10. Let-7c-5p down-regulates immune-related CDCA8 to inhibit hepatocellular carcinoma.
Chen W; Wang H; Shen Y; Wang S; Liu D; Zhao H; Wang G; Huang F; Wang W; Wu R; Hou L; Ye Z; Zhang X; Geng X; Yu X
Funct Integr Genomics; 2023 Feb; 23(1):56. PubMed ID: 36737507
[TBL] [Abstract][Full Text] [Related]
11. Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma.
Deng L; Ren Z; Jia Q; Wu W; Shen H; Wang Y
BMC Cancer; 2013 Jul; 13():363. PubMed ID: 23895220
[TBL] [Abstract][Full Text] [Related]
12. let-7g sensitized liver cancer cells to 5-fluorouracil by downregulating ABCC10 expression.
Chen Y; Zhang B; Zhong C; Zhou Y; Xue L; Luo C; Yi L; Gong Q; Long Y
Chem Biol Drug Des; 2024 Jan; 103(1):e14396. PubMed ID: 38054583
[TBL] [Abstract][Full Text] [Related]
13. MEL-pep, an analog of melittin, disrupts cell membranes and reverses 5-fluorouracil resistance in human hepatocellular carcinoma cells.
Ke M; Dong J; Wang Y; Zhang J; Zhang M; Wu Z; Lv Y; Wu R
Int J Biochem Cell Biol; 2018 Aug; 101():39-48. PubMed ID: 29800725
[TBL] [Abstract][Full Text] [Related]
14. Targeting mTORC1/2 Complexes Inhibit Tumorigenesis and Enhance Sensitivity to 5-Flourouracil (5-FU) in Hepatocellular Carcinoma: A Preclinical Study of mTORC1/2-Targeted Therapy in Hepatocellular Carcinoma (HCC).
Zhang Y; Jia QA; Kadel D; Zhang XF; Zhang QB
Med Sci Monit; 2018 May; 24():2735-2743. PubMed ID: 29720580
[TBL] [Abstract][Full Text] [Related]
15. Caffeine enhances the anti-tumor effect of 5-fluorouracil via increasing the production of reactive oxygen species in hepatocellular carcinoma.
Wang Z; Gu C; Wang X; Lang Y; Wu Y; Wu X; Zhu X; Wang K; Yang H
Med Oncol; 2019 Oct; 36(12):97. PubMed ID: 31664534
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).
Jin J; Huang M; Wei HL; Liu GT
World J Gastroenterol; 2002 Dec; 8(6):1029-34. PubMed ID: 12439919
[TBL] [Abstract][Full Text] [Related]
17. let-7b and let-7c are determinants of intrinsic chemoresistance in renal cell carcinoma.
Peng J; Mo R; Ma J; Fan J
World J Surg Oncol; 2015 May; 13():175. PubMed ID: 25951903
[TBL] [Abstract][Full Text] [Related]
18. Let-7c microRNA expression and clinical significance in hepatocellular carcinoma.
Zhu XM; Wu LJ; Xu J; Yang R; Wu FS
J Int Med Res; 2011; 39(6):2323-9. PubMed ID: 22289550
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells.
Tomimaru Y; Eguchi H; Nagano H; Wada H; Tomokuni A; Kobayashi S; Marubashi S; Takeda Y; Tanemura M; Umeshita K; Doki Y; Mori M
Br J Cancer; 2010 Nov; 103(10):1617-26. PubMed ID: 20978511
[TBL] [Abstract][Full Text] [Related]
20. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells.
Gu W; Liu L; Fang FF; Huang F; Cheng BB; Li B
Oncol Rep; 2014 Jan; 31(1):216-22. PubMed ID: 24173654
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
